Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 3/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24985771 | 1.00 | CFTR (0.33) | CFTRADORA2AADORA2BADORA1GABRA5 | |
| SCHEMBL24986096 | 0.93 | CFTR (0.35) | CFTRGABRA5POLBKMT2A | |
| SCHEMBL24986097 | 0.93 | CFTR (0.35) | CFTRGABRA5POLBKMT2A | |
| SCHEMBL25114674 | 0.93 | CFTR (0.31) | CFTRGABRA5 | |
| SCHEMBL25114673 | 0.93 | CFTR (0.31) | CFTRGABRA5 | |
| SCHEMBL24984700 | 0.92 | CFTR (0.31) | CFTRGABRA5 | |
| SCHEMBL24986149 | 0.92 | CFTR (0.33) | CFTRGABRA5POLBKMT2A | |
| SCHEMBL24986153 | 0.92 | CFTR (0.33) | CFTRGABRA5POLBKMT2A | |
| SCHEMBL25113796 | 0.92 | CFTR (0.33) | CFTRADORA2AADORA2BADORA1GABRA5 | |
| SCHEMBL25113797 | 0.92 | CFTR (0.33) | CFTRADORA2AADORA2BADORA1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572367-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572367-B2 | Antiviral heterocyclic compounds | ACE, HPRT1, ACE2 | CFTR 283/4885ADORA2A 1668/4885ADORA2B 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.